VERU INC.
VERU evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VERU—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VERU
VERU INC. is a late clinical-stage biopharmaceutical company developing enobosarm (a SARM) for high-quality weight loss and sabizabulin (a microtubule disruptor) for anti-inflammatory indications, with a focus on cardiometabolic and inflammatory diseases [sec_mda · as of 2025-02-13].
Key risk: Novo Nordisk agreement termination
BioSniper Score
Based on 6 of 6 signals
Market Cap
$44.8M
Cash Runway
13.7 moLead Asset
enobosarm (Phase 2)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 4 catalysts for VERU INC..
VERU INC. is a late clinical-stage biopharmaceutical company developing enobosarm (a SARM) for high-quality weight loss and sabizabulin (a microtubule disruptor) for anti-inflammatory indications, with a focus on cardiometabolic and inflammatory diseases [sec_mda · as of 2025-02-13].
- Cash and equivalents were $23.9M as of 2026-06-30 [sec].
- Net loss for the quarter ended June 30, 2026 was -$7.0M [sec].
- Shareholders' equity was $18.3M as of 2026-06-30 [sec].
- The company is not profitable and has had negative cash flow from operations [sec_mda · as of 2026-05-13].
- Key pipeline includes enobosarm (Phase 2b PLATEAU study) and sabizabulin (anti-inflammatory) [sec_mda · as of 2025-02-13].
What works
- Enobosarm is being developed in combination with GLP-1 receptor agonists to augment fat loss and prevent muscle loss, addressing a growing market in high-quality weight loss [sec_mda · as of 2025-02-13].
- The company has a supply agreement with Novo Nordisk for the PLATEAU Phase 2b trial, indicating external validation and collaboration [sec · filed 2026-06-04].
- Cash position improved to $23.9M as of June 30, 2026 from $15.8M at September 30, 2025, providing near-term operational runway [sec_mda · as of 2026-08-10].
What to weigh
- The company is not profitable and has had negative cash flow from operations, requiring substantial additional capital to support drug development and commercialization [sec_mda · as of 2026-05-13].
- The supply agreement with Novo Nordisk can be terminated for convenience upon 60 days' notice, introducing partnership risk [sec · filed 2026-06-04].
- Clinical development risks include the possibility that trial results may be insufficient to meet regulatory standards or warrant continued development [sec · filed 2026-06-04].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“Our cash, cash equivalents, and restricted cash on hand at June 30, 2026 was $23.9 million”
SEC MD&A · August 10, 2026
Company is not profitable and needs capital
“The Company is not profitable and has had negative cash flow from operations. We will need substantial capital to support our drug development and any related commercialization efforts for our drug candidates.”
SEC MD&A · May 13, 2026
Novo Nordisk supply agreement termination risk
“the risk that the Supply Agreement with Novo Nordisk could be terminated prior to the completion of the Company's PLATEAU Phase 2b clinical trial, including pursuant to a provision that permits Novo Nordisk to terminate for convenience upon 60 days' prior notice”
SEC filings · June 4, 2026
Enobosarm development focus
“Enobosarm, an oral selective androgen receptor modulator ("SARM"), is initially being developed as a treatment to augment fat loss and to prevent lean mass (muscle) loss in sarcopenic obese or overweight older patients receiving a GLP-1 RA”
SEC MD&A · February 13, 2025
Catalyst timeline
- 2026-12-31 · Phase2_Topline · enobosarm — Phase 2 Readout: enobosarm — Interim data from the Phase 2b PLATEAU clinical study of enobosarm is expected.
- 2027-03-31 · Phase2_Topline · enobosarm — Phase 2 Readout: enobosarm — Phase 2 topline data readout for enobosarm in high quality weight loss is expected.
- 2027-03-31 · Phase2_Topline · enobosarm + semaglutide — Phase 2 Readout: enobosarm + semaglutide — Phase 2 topline data readout for enobosarm + semaglutide in obesity is expected in the first quarter of 2027.
- 2027-12-31 · Phase2_Topline · enobosarm — Phase 2 Readout: enobosarm — Additional Phase 2 topline data readout for enobosarm is expected.
Risks & what to watch (3)›
Key risks
- Novo Nordisk agreement termination — Supply agreement can be terminated for convenience on 60 days' notice, risking trial disruption [sec · filed 2026-06-04].
- Negative cash flow and capital need — Company is not profitable and requires substantial additional capital for development and commercialization [sec_mda · as of 2026-05-13].
- Clinical trial failure risk — Trial results may be insufficient to meet regulatory standards or warrant continued development [sec · filed 2026-06-04].
What to watch
- Phase 2 topline data for enobosarm expected in Q4 2026 [catalyst].
- Phase 2 topline data for enobosarm + semaglutide expected in Q1 2027 [catalyst].
- Phase 2 topline data for enobosarm (high quality weight loss) expected in Q1 2027 [catalyst].
- Additional Phase 2 topline data for enobosarm expected in Q4 2027 [catalyst].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run VERU INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VERU INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
13.7 months
D/E 0.30
Lead: Phase 3
2 candidates
4 upcoming, next in ~123d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$7.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,078,764 | $2.4M |
| alyeska investment group, l.p. | 1,000,000 | $2.2M |
| oppenheimer & co inc | 196,300 | $434K |
| geode capital management, llc | 184,622 | $408K |
| millennium management llc | 150,401 | $332K |
| blackrock, inc. | 114,169 | $252K |
| citadel advisors llc | 81,882 | $181K |
| vanguard fiduciary trust co | 80,653 | $178K |
| choreo, llc | 75,263 | $166K |
| renaissance technologies llc | 69,250 | $153K |
Showing top 10 of 55 institutional holders of VERU INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 4.5%
- Days to cover
- 12.4
- Shares short
- 656,045
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VERU short interestGovernance
Frequently asked questions
What is the AI investment thesis for VERU INC.?
VERU INC. is a late clinical-stage biopharmaceutical company developing enobosarm (a SARM) for high-quality weight loss and sabizabulin (a microtubule disruptor) for anti-inflammatory indications, with a focus on cardiometabolic and inflammatory diseases [sec_mda · as of 2025-02-13].
What is VERU INC.'s lead drug candidate?
VERU INC.'s most advanced tracked candidate is enobosarm (Phase 2) for Muscle Loss; Obesity & Overweight.
What is VERU INC.'s next catalyst?
VERU INC.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: enobosarm" — expected December 31, 2026.
Who is the CEO of VERU INC.?
Dr. Mitchell S. Steiner F.A.C.S., M.D. is the chief executive officer of VERU INC. (VERU).
Where is VERU INC. headquartered?
VERU INC. (VERU) is headquartered in Miami, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.